2.19
+3.30%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Veru
From its filings with the US Securities and Exchange Commission
Veru is based in Miami, Florida and is incorporated in Wisconsin. Its shares trade on Nasdaq under the ticker VERU. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 September 2024, it reported revenue of $16.9m.
We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and inflammatory diseases. Our drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator (“SARM”), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass. This activity leads to improved body composition and physical function with expected clinically meaningful incremental weight reduction versus GLP-1 RA monotherapy. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. On December 30, 2024, the Company sold its FDA-approved commercial product, the FC2 Female Condom® (Internal Condom), for the dual protection against unplanned pregnancy and sexually transmitted infections (the “FC2 Business”).
Veru is a Wisconsin corporation that is the successor to The Wisconsin Pharmacal Company, Inc. (“Wisconsin Pharmacal”), a company which manufactured and marketed disparate specialty chemical and branded consumer products. Wisconsin Pharmacal was originally incorporated in 1971.
Quoted from its 10-K, filed 17 Dec 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Products
- Listed since
- 19 Jul 1990
- Employees
- 20
- Website
- verupharma.com ↗
- Head office
- 2916 N. MIAMI AVENUE, MIAMI, FL, 33127
- Incorporated in
- WI
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Mitchell SteinerChairman of the Board, President, Chief Executive Officer, since 2016$2.0m
- Dr. Harry FischVice Chairman of the Board, Chief Corporate Officer, since 2016$848,635
- Ms. Michele GrecoChief Financial Officer, Chief Administrative Officer$1.5m
- Dr. K. Gary BarnetteChief Scientific Officer$1.0m
- Ms. Grace HyunIndependent Director$61,788
- Mr. Loren KatzovitzIndependent Director$54,640
- Dr. Lucy LuIndependent Director$63,416
- Mr. Michael RankowitzIndependent Director$60,974
- Mr. Samuel FischExecutive Director, Investor Relations and Corporate Communications, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 72
- Environment
- 75
- Social
- 90
- Governance
- 50
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Veru's FC2 Female Condom provides protection against pregnancy and STIs in the Consumer Staples sector.
- VERU-111 targets microtubules for prostate cancer treatment in the oncology pipeline.
- The Commercial segment includes FC2, a key product for the Consumer Staples market.
Weaknesses
- The company employs 386 full-time employees, which is relatively small for a biopharmaceutical firm.
- Veru's research pipeline focuses on prostate cancer with VERU-100 and Zuclomiphene Citrate.
- The firm's Commercial segment is limited to FC2, a single product in Consumer Staples.
Opportunities
- Expanding FC2 distribution in the US market could increase Consumer Staples revenue.
- VERU-111's microtubule targeting may attract oncology partnerships.
- The urology segment in Research and Development offers new drug development potential.
Threats
- Prostate cancer treatments face competition from established oncology drugs.
- The Consumer Staples sector has high regulatory scrutiny for product safety.
- R&D delays could impact the launch of VERU-100 and Zuclomiphene Citrate.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.